Iwona Tomaszewska

Dr. Iwona Tomaszewska


Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
OGOn behalf of the EORTC Quality of Life Group
On behalf of the EORTC Quality of Life Group
SSSamantha Sodergren
Samantha Sodergren
Olga HussonOlga Husson
Olga Husson
JRJessica Robinson
Jessica Robinson
GRGudrun E. Rohde
Gudrun E. Rohde
ADAnne-Sophie Darlington
Anne-Sophie Darlington
Purpose For adolescents and young adults (AYAs), the impact of a cancer diagnosis and subsequent treatment is likely to be distinct from other age groups given the unique and complex psychosocial challenges of this developmental phase. In this review of the literature, we report the health-related quality of life (HRQoL) issues experienced by AYAs diagnosed with cancer and undergoing treatment. Methods MEDLINE, EMBASE, CINAHL, PsychINFO and the Cochrane Library Databases were searched for publications reporting HRQoL of AYAs. Issues generated from interviews with AYAs or from responses to patient reported outcome measures (PROMs) were extracted. Results 166 papers were reviewed in full and comprised 72 papers covering 69 primary studies, 49 measurement development or evaluation papers and 45 reviews. Of the 69 studies reviewed, 11 (16%) used interviews to elicit AYAs’ descriptions of HRQoL issues. The majority of the PROMs used in the studies represent adaptations of paediatric or adult measures. HRQoL issues were organised into the following categories: physical, cognitive, restricted activities, relationships with others, fertility, emotions, body image and spirituality/outlook on life. Conclusion The HRQoL issues presented within this review are likely to be informative to health care professionals and AYAs. The extensive list of issues suggests that the impact of a cancer diagnosis and treatment during adolescence and young adulthood is widespread and reflects the complexities of this developmental phase.

21 March 2017 in PeerJ
Verified
Journal Article
Open access
PDF file
Brandon Michael HenryBrandon Michael Henry
Brandon Michael Henry
SSSilvia Sanna
Silvia Sanna
MGMatthew J. Graves
Matthew J. Graves
JVJens Vikse
Jens Vikse
BSBeatrice Sanna
Beatrice Sanna
KTKrzysztof A. Tomaszewski
Krzysztof A. Tomaszewski
Background: The Non-Recurrent Laryngeal Nerve (NRLN) is a rare embryologically-derived variant of the Recurrent Laryngeal Nerve (RLN). The presence of an NRLN significantly increases the risk of iatrogenic injury and operative complications. Our aim was to provide a comprehensive meta-analysis of the overall prevalence of the NRLN, its origin, and its association with an aberrant subclavian artery.Methods: Through March 2016, a database search was performed of PubMed, CNKI, ScienceDirect, EMBASE, BIOSIS, SciELO, and Web of Science. The references in the included articles were also extensively searched. At least two reviewers judged eligibility and assessed and extracted articles. MetaXL was used for analysis, with all pooled prevalence rates calculated using a random effects model. Heterogeneity among the included studies was assessed using the Chi2test and the I2statistic.Results: Fifty-three studies (33,571 right RLNs) reported data on the prevalence of a right NRLN. The pooled prevalence estimate was 0.7% (95% CI [0.6–0.9]). The NRLN was found to originate from the vagus nerve at or above the laryngotracheal junction in 58.3% and below it in 41.7%. A right NRLN was associated with an aberrant subclavian artery in 86.7% of cases.Conclusion: The NRLN is a rare yet very clinically relevant structure for surgeons and is associated with increased risk of iatrogenic injury, most often leading to temporary or permanent vocal cord paralysis. A thorough understanding of the prevalence, origin, and associated pathologies is vital for preventing injuries and complications.

15 May 2014 in Head & Neck
Verified
Journal Article
Closed access
PDF file
SSSusanne Singer
Susanne Singer
CACláudia Araújo
Cláudia Araújo
JAJuan Ignacio Arraras
Juan Ignacio Arraras
IBIngo Baumann
Ingo Baumann
ABAndreas Boehm
Andreas Boehm
OGOn Behalf Of The Eortc Quality Of Life And The Eortc Head And Neck Cancer Groups
On Behalf Of The Eortc Quality Of Life And The Eortc Head And Neck Cancer Groups

1 November 2016 in Thyroid®
Verified
Journal Article
Closed access
SSSusanne Singer
Susanne Singer
Olga HussonOlga Husson
Olga Husson
ITIwona Tomaszewska
Iwona Tomaszewska
LLLaura Locati
Laura Locati
NKNAOMI KIYOTA
NAOMI KIYOTA
TFThe Eortc Endocrine Task Force
The Eortc Endocrine Task Force
Background: The objectives of this study were to determine quality of life (QoL) issues that are relevant to thyroid cancer patients cross-culturally, and to identify those with highest relevance to them in addition to the more general issues covered by the core European Organisation for Research and Treatment of Cancer QoL questionnaire (EORTC QLQ-C30). Methods: A systematic literature search provided a list of potentially relevant QoL issues to supplement the core questionnaire EORTC QLQ-C30, which is widely used in research and in care and addresses QoL issues relevant to all groups of cancer patients. A panel of experts revised this list, and thyroid cancer patients rated the issues regarding their relevance for QoL by selecting the 25 issues that they would include in a thyroid cancer–specific QoL module. Results: The literature search and expert discussion provided a list of 71 QoL issues that was rated by thyroid cancer patients (n = 110) from seven countries. All issues were of high priority to at least some of the patients. The most frequently selected issues were sudden attacks of tiredness, exhaustion, quality of sleep, employment, social support, fear of cancer progression, fear of second operation, difficulties swallowing, and globus sensation. Conclusions: Thyroid cancer patients cross-culturally rate fatigue-related issues as highly important for their QoL, calling for increased efforts to find successful treatments for this problem. Vocational rehabilitation is also highly relevant for them and should therefore be an important aim of multidisciplinary care. The third important area of concern is psychological issues, especially fear of progression and of additional treatments.

5 August 2014 in Journal of Anatomy
Verified
Journal Article
Open access
PDF file
ITIwona Tomaszewska
Iwona Tomaszewska
KTKrzysztof A. Tomaszewski
Krzysztof A. Tomaszewski
EKElizabeth K. Kmiotek
Elizabeth K. Kmiotek
IPIwona Z. Pena
Iwona Z. Pena
AUAndrzej Urbanik
Andrzej Urbanik
JWJerzy A. Walocha
Jerzy A. Walocha
Accurate knowledge of greater palatine foramen (GPF) anatomy is necessary when performing a variety of anaesthesiological, dental or surgical procedures. The first aim of this study was to localize the GPF in relation to multiple anatomical landmarks. The second aim was to perform a systematic review of literature, and to conduct a meta‐analysis on the subject of GPF position to aid clinicians in their practice. One‐hundred and fifty dry, adult, human skulls and 1200 archived head computed tomography scans were assessed and measured in terms of GPF relation to other anatomical reference points. A systematic literature search was performed using the PubMed, Embase and Web of Science databases, and a meta‐analysis on the subject of GPF relation to the maxillary molars was conducted. On average, in the Polish population, the GPF was positioned 15.9 ± 1.5 mm from the midline maxillary suture (MMS), 3.0 ± 1.2 mm from the alveolar ridge (AR) and 17.0 ± 1.5 mm from the posterior nasal spine (PNS); 74.7% of GPF were positioned opposite the third maxillary molar (M3). Twenty‐seven studies were included in the systematic review and 23 in the meta‐analysis (n = 6927 GPF). The pooled prevalence of the GPF being positioned opposite the M3 was 63.9% (95% confidence interval = 56.6–70.9%). Concluding, the GPF is most often located opposite the M3 in the majority of the world's populations. The maxillary molars are the best landmarks for locating the GPF. In edentulous patients the most useful points for approximating the position of the GPF are the AR, MMS and PNS. This study introduces an easy and repeatable classification to reference the GPF to the maxillary molars.

22 August 2017 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MKMichael Koller
Michael Koller
MHM.J. Hjermstad
M.J. Hjermstad
KTKrzysztof A. Tomaszewski
Krzysztof A. Tomaszewski
ITIwona Tomaszewska
Iwona Tomaszewska
KHK. Hornslien
K. Hornslien
ABA. Bottomley
A. Bottomley
The European Organization for Research and Treatment of Cancer (EORTC) QLQ-LC13 was the first module to be used in conjunction with the core questionnaire, the QLQ-C30. Since the publication of the LC13 in 1994, major advances have occurred in the treatment of lung cancer. Given this, an update of the EORTC QLQ-LC13 was undertaken. The study followed phases I to III of the EORTC Module Development Guidelines. Phase I generated relevant quality-of-life issues using a mix of sources including the involvement of 108 lung cancer patients. Phase II transformed issues into questionnaire items. In an international multicenter study (phase III), patients completed both the EORTC QLQ-C30 and the 48-item provisional lung cancer module generated in phases I and II. Patients rated each of the items regarding relevance, comprehensibility, and acceptance. Patient ratings were assessed against a set of prespecified statistical criteria. Descriptive statistics and basic psychometric analyses were carried out. The phase III study enrolled 200 patients with histologically confirmed lung cancer from 12 centers in nine countries (Cyprus, Germany, Italy, Israel, Spain, Norway, Poland, Taiwan, and the UK). Mean age was 64 years (39 − 91), 59% of the patients were male, 82% had non-small-cell lung cancer, and 56% were treated with palliative intent. Twenty-nine of the 48 questions met the criteria for inclusion. The resulting module with 29 questions, thus currently named EORTC QLQ-LC29, retained 12 of the 13 original items, supplemented with 17 items that primarily assess treatment side-effects of traditional and newer therapies.